Daré Bioscience to Present at 2021 BIO Digital

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) will present at the 2021 BIO Digital virtual event from June 10-11 and 14-18, 2021. CEO Sabrina Martucci Johnson will discuss the company's portfolio of innovative investigational products beginning June 10 at 9 a.m. ET. The presentation will be accessible to registered attendees on-demand. Following the event, a recording will be available on Daré's investor relations website until July 2, 2021. Daré is focused on advancing women's health through unique products, including Ovaprene® and Sildenafil Cream, among others.

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.

Sabrina Martucci Johnson, President and CEO of Daré, will provide an overview of the Company’s portfolio of innovative investigational products. The presentation will be available on demand to registered attendees beginning on June 10^th at 9 a.m. Eastern Time. Registration information for 2021 BIO Digital can be found here.

Following the conclusion of the event, a recording of Ms. Johnson’s presentation will be available under “Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com until July 2, 2021.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, investigational hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.

About BIO

BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Contact:

Investors on behalf of Daré Bioscience, Inc.:
Tom Masterson
Allele Capital Partners
tmasterson@allelecapital.com
646.573.3216

Source: Daré Bioscience, Inc.

FAQ

What is the date of Daré Bioscience's presentation at the 2021 BIO Digital?

Daré Bioscience's presentation is scheduled for June 10, 2021.

Who will represent Daré Bioscience at the BIO Digital event?

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will represent the company.

Where can I watch Daré Bioscience's presentation after the event?

The recording of the presentation will be available on Daré's investor relations website until July 2, 2021.

What innovative products will Daré Bioscience discuss at the BIO Digital?

Daré will showcase its portfolio including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1.

How can I register for the 2021 BIO Digital event?

Registration information for the 2021 BIO Digital can be found on their official website.